Trending NewsTrending NewsTop-Rated StocksTop-RatedNYSE:BHVN Biohaven (BHVN) Stock Price, News & Analysis $14.77 -0.33 (-2.19%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$14.59 -0.18 (-1.25%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biohaven Stock (NYSE:BHVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biohaven alerts:Sign Up Key Stats Today's Range$14.30▼$15.0950-Day Range$12.81▼$17.0852-Week Range$12.79▼$55.70Volume2.46 million shsAverage Volume1.82 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$58.46Consensus RatingBuy Company Overview Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Read More Biohaven Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreBHVN MarketRank™: Biohaven scored higher than 48% of companies evaluated by MarketBeat, and ranked 560th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBiohaven has received a consensus rating of Buy. The company's average rating score is 3.07, and is based on 12 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBiohaven has only been the subject of 3 research reports in the past 90 days.Read more about Biohaven's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biohaven are expected to grow in the coming year, from ($8.90) to ($6.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biohaven is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biohaven is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiohaven has a P/B Ratio of 3.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Biohaven's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted13.20% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Biohaven has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiohaven does not currently pay a dividend.Dividend GrowthBiohaven does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted13.20% of the outstanding shares of Biohaven have been sold short.Short Interest Ratio / Days to CoverBiohaven has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Biohaven has recently increased by 10.13%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.33 News SentimentBiohaven has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Biohaven this week, compared to 9 articles on an average week.Search InterestOnly 9 people have searched for BHVN on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.MarketBeat Follows4 people have added Biohaven to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biohaven insiders have not sold or bought any company stock.Percentage Held by Insiders16.00% of the stock of Biohaven is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions88.78% of the stock of Biohaven is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biohaven's insider trading history. Receive BHVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter. Email Address BHVN Stock News HeadlinesBiohaven Ltd. (BHVN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitAugust 1 at 12:00 PM | prnewswire.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BiohavenAugust 1 at 10:45 AM | globenewswire.comThis Crypto Is Set to Explode in JanuaryThis Could Be the Most Important Crypto Law in History While the world celebrates Bitcoin becoming 2025’s top-performing asset, smart hedge funds are accumulating elsewhere. During the upcoming Crypto Hedge Fund Summit, you'll discover exactly which coins they’ve loaded up on before this historic vote.August 2 at 2:00 AM | Crypto 101 Media (Ad)Pomerantz Law Firm Announces the Filing of a Class Action Against Biohaven Ltd. and Certain Officers – BHVNAugust 1 at 10:00 AM | globenewswire.comShareholders that lost money on Biohaven Ltd.(BHVN) should contact Levi & Korsinsky about pending Class Action - BHVNAugust 1 at 9:00 AM | prnewswire.comBHVN Investors Have Opportunity to Lead Biohaven Ltd. Securities Fraud LawsuitJuly 31 at 5:38 PM | prnewswire.comShareholders of Biohaven Ltd. Should Contact Levi & Korsinsky Before September 12, 2025 to Discuss Your Rights – BHVNJuly 31 at 4:07 PM | globenewswire.comDeadline Alert: Biohaven Ltd. (BHVN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud LawsuitJuly 31 at 12:00 PM | globenewswire.comSee More Headlines BHVN Stock Analysis - Frequently Asked Questions How have BHVN shares performed this year? Biohaven's stock was trading at $37.35 on January 1st, 2025. Since then, BHVN shares have decreased by 60.5% and is now trading at $14.77. How were Biohaven's earnings last quarter? Biohaven Ltd. (NYSE:BHVN) issued its quarterly earnings results on Monday, May, 12th. The company reported ($2.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.67) by $0.50. When did Biohaven IPO? Biohaven (BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers. Who are Biohaven's major shareholders? Top institutional investors of Biohaven include WCM Investment Management LLC (0.29%), TD Asset Management Inc (0.29%), Y Intercept Hong Kong Ltd (0.25%) and Envestnet Asset Management Inc. (0.06%). Insiders that own company stock include John W Childs, Vlad Coric, Gregory Bailey, Matthew Buten and Irina Antonijevic. View institutional ownership trends. How do I buy shares of Biohaven? Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biohaven own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biohaven investors own include NVIDIA (NVDA), Humana (HUM), Invesco QQQ (QQQ), Meta Platforms (META), American Water Works (AWK), Broadcom (AVGO) and Voyager Therapeutics (VYGR). Company Calendar Last Earnings5/12/2025Today8/02/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNYSE:BHVN Previous SymbolNASDAQ:BHVN CIK1935979 Webwww.biohavenpharma.com Phone203-404-0410FaxN/AEmployees239Year FoundedN/APrice Target and Rating Average Price Target for Biohaven$58.46 High Price Target$76.00 Low Price Target$21.00 Potential Upside/Downside+295.8%Consensus RatingBuy Rating Score (0-4)3.07 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($9.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$846.42 million Net MarginsN/A Pretax MarginN/A Return on Equity-257.07% Return on Assets-164.01% Debt Debt-to-Equity RatioN/A Current Ratio2.33 Quick Ratio2.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.19 per share Price / Book3.53Miscellaneous Outstanding Shares102,110,000Free Float85,775,000Market Cap$1.51 billion OptionableOptionable Beta0.98 Social Links 10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NYSE:BHVN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biohaven Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biohaven With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.